Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
SUNITINIB SUN (Sun Pharma ANZ Pty Ltd)
Product name
SUNITINIB SUN
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
149 (255 working days)
Active ingredients
sunitinib malate
Registration type
New generic medicine
Indication
SUNITINIB SUN (capsule) is indicated for:
- treatment of advanced renal cell carcinoma (RCC)
- treatment of gastrointestinal stromal tumour (GIST) after failure of imatinib mesilate treatment due to resistance or intolerance
- treatment of unresectable, well-differentiated pancreatic neuroendocrine tumours (pancreatic NET).